The production of proinflammatory cytokines and chemokines, when localized to infected tissues, makes the local environment more favorable in fighting infection. When these mediators spill over into the systemic circulation; however, they are responsible for the signs and symptoms of sepsis. The pathophysiologic features of acute sepsis are therefore largely attributable to the host's innate immune response to the offending pathogen. The innate immune system includes leukocytes such as
Introduction
The proinflammatory response to infection is typically responsible for the classical signs and symptoms of sepsis such as fever, tachycardia, tachypnea, capillary leak, and organ dysfunction. This element of the host response has been targeted in numerous clinical trials in septic adults, in which anti-inflammatory therapies were employed in an effort to ameliorate the proinflammatory surge. The failure of most of these trials to improve outcomes led to the investigation of the counter-regulatory immune response to sepsis. In the last two decades, multiple investigators have identified an overly robust compensatory anti-inflammatory response to sepsis in some patients. This state, termed "immunoparalysis," has been associated with adverse outcomes including increased risks for nosocomial infection, prolonged organ dysfunction, and death. In this review, we will identify elements of the pro-and anti-inflammatory responses to pediatric sepsis, approaches to monitoring the immune response in septic children, and potential strategies for immunomodulation in pediatric sepsis with a goal of restoring immunologic balance. neutrophils, dendritic cells, monocytes, and macrophages. These cells broadly recognize and are activated by pathogenassociated molecular patterns (PAMP), such as lipopolysaccharide (LPS) though the ligation of constitutively expressed cell surface receptors. The best described of these are the toll-like receptors (TLR 1 ). This family of PAMP receptors includes those that can recognize a wide variety of molecules that are expressed by pathogens but not human cells. Upon activation, innate immune cells can ingest pathogens and kill them through enzymatic action or exposure to reactive oxygen species. Innate immune cells then digest the pathogen's proteins into antigenic peptides that are then loaded onto class II major histocompatibility complex (MHC) molecules, such as human leukocyte antigen (HLA)-DR. These antigens can then be presented to lymphocytes, members of the adaptive immune system. Finally, activated innate immune cells make proinflammatory cytokines which modulate the local environment to promote clearance of infection, along with chemokines which serve to attract other leukocytes to the area along concentration gradients. The innate immune response does not require prior exposure to a pathogen and should be of the same magnitude with each exposure. The adaptive immune system consists of T and B lymphocytes. These cells typically, though not always, require activation through interaction with an antigen-bearing innate immune cell. The response is highly antigen-specific and is of greater magnitude and rapidity with subsequent exposures to an antigen. Activated B cells develop into plasma cells which produce antibody. T cells can be divided, based on cell surface marker expression, into CD4þ helper T cell and CD8þ cytotoxic T cell populations. Cytotoxic T cells promote cellular killing through elaboration of lytic enzymes. Helper T cells produce cytokines that modulate and perpetuate the immune response. Naïve helper T cells can differentiate into one of many subtypes depending on the signals they receive from antigen-presenting cells and the cytokine milieu in which they are activated. T helper (T H )-1 cells are proinflammatory and produce cytokines including interferon (IFN)-γ and interleukin (IL)-2. T H 2 cells promote anti-inflammatory and autoimmune/allergic responses through ela-boration of IL-10, IL-4, and IL-13. IL-17 that produces T H 17 cells are potently proinflammatory while regulatory T cells (T reg ) are anti-inflammatory through production of IL-10, transforming growth factor (TGF)-β, and through direct, cellcontact-mediated inhibition. Innate and adaptive immune cells, their actions, and mediators are listed in ►Table 1.
Immunologic Balance
The systemic inflammatory response syndrome (SIRS) represents the clinical manifestation of the systemic proinflammatory response. The clinical phenotype of fever, tachycardia, tachypnea, and capillary leak is common to most inflammatory conditions including sepsis. However, every major biologic pathway has a counter-regulatory system. The compensatory anti-inflammatory response syndrome (CARS) is the "off switch" for the proinflammatory response (►Fig. 1). The CARS response has no clinical phenotype but is characterized by several important physiologic elements. First, within minutes to hours of the proinflammatory response becoming activated, innate and adaptive leukocytes can down-regulate intracellular signaling and become hyporesponsive to stimulation. This period of quiescence serves to rein in the proinflammatory response and potentially avoid systemic spillover of cytokines. Second, leukocyte cell death can occur either as a result of their initial activation (e.g., neutrophils) or as the result of apoptosis (e.g., lymphocytes). Third, surviving innate and adaptive leukocytes can skew their cytokine production toward the production of anti-inflammatory mediators, such as IL-10. While it is likely beneficial to the host if brief and modest in magnitude, the CARS response can become pathological if severe and prolonged. In this setting, it is termed immunoparalysis and it represents an important form of acquired immune deficient which is very prevalent in the intensive care unit (ICU).
Immunoparalysis in Sepsis
The CARS response is quantifiable in the research laboratory and several approaches to the diagnosis of immunoparalysis have been undertaken in septic patients. The antigen presenting molecule HLA-DR should be expressed robustly on the surface of circulating monocytes. HLA-DR molecules are internalized as part of the CARS response and this can be quantified using flow cytometry. In a state of health, > 90% of circulating monocytes should stain positive for HLA-DR, while a monocyte HLA-DR (mHLA-DR) expression level of < 30% is associated with increased risks for nosocomial infection and death. [2] [3] [4] An alternate method allows for the quantitation of molecules of HLA-DR per cell, also using flow cytometry. A threshold of < 8,000 molecules per cell has been used in adult studies to define immunoparalysis with < 5,000 molecules per cell representing the most severe suppression. 5, 6 Thresholds of mHLA-DR expression that are associated with adverse outcomes from pediatric sepsis are less clear, with one recent study suggesting that the change in mHLA-DR expression over time may be more important that absolute thresholds. Manzoli et al found that mortality, in a 30-subject cohort of septic children, was associated with failure to increase mHLA-DR by at least 1,000 molecules per cell over the first week after sepsis onset. 7 An alternative method to the diagnosis of immunoparalysis is the use of ex vivo stimulation of whole blood to identify subjects whose leukocytes are hyporesponsive. The whole blood ex vivo LPS-induced tumor necrosis factor (TNF)-α production capacity assay measures the ability of circulating innate immune cells to response to a new stimulus. In this assay, whole blood is added to a tube containing standardized LPS stimulation reagent and incubated for a period of time after which TNFα levels are measured in the supernatant. Healthy children's blood should produce large amounts of TNFα upon incubation with LPS. Marked reduction in the TNFα response is a feature of CARS with severe reductions being characteristic of immunoparalysis. It is important to note that the use of the TNFα response to evaluate innate immune function does not assign particular significance to TNFα itself or to the TLR4/CD14 pathway through which LPS signals. Rather, the TNFα response is used as a surrogate for the broader responsiveness of the innate immune cell by virtue of TNFα's favorable kinetics and relative ease of measurement. In the most widely reported approach to this type of testing, a TNFα response less than approximately 200 pg/mL has been associated with increased risks for the development of nosocomial infection, prolonged organ dysfunction, and death in single-and multicenter cohorts of septic children. 2, 8, 9 Thresholds of TNFα response that are associated with adverse outcomes may vary depending on the type of LPS used, blood volume used, incubation conditions, and the outcome being considered. The adaptive immune system can also be affected as part of the CARS response. Lymphocyte apoptosis is common in the aftermath of sepsis, with peripheral lymphopenia and splenic lymphocyte depletion, having been associated with multiple organ dysfunction syndrome (MODS) and death in septic adults and children. [10] [11] [12] Downregulation of lymphocyte responsiveness has similarly been associated with adverse outcomes from sepsis. Wong et al performed mRNA profiling on peripheral blood leukocytes early in the course of pediatric septic shock and evaluated expression of 100 genes corresponding to adaptive immunity and glucocorticoid receptor signaling. 13 They identified two distinct patterns of gene expression or endotypes that were prevalent in the cohort, one with predominately suppressed gene expression and another with a substantially greater proportion of activated genes. Risks for mortality and prolonged MODS were significantly higher in children with the more suppressed endotype. Lymphocyte suppression at the protein level has also been shown to predict outcomes from sepsis. Adaptive immune testing can also utilize ex vivo stimulation as a tool for evaluating cellular responsiveness. Instead of using LPS as a stimulant, one must use a lymphocyte stimulant such as phytohemagglutinin (PHA) or anti-CD3/anti-CD28 antibodies. Multiple cytokines have been evaluated as readouts from lymphocyte stimulation in this setting but reduced capacity to produce IFNγ in response to ex vivo stimulation has been associated with the development of infectious complications, prolonged organ failure, and death in septic children and adults. 9, 11, 14, 15 The timing of innate and adaptive immune suppression is somewhat controversial in the field. Early work with innate immune function in septic adults suggested that very early suppression (e.g., days 1-2 of illness) was less predictive of adverse outcomes than were samples obtained later in the course (e.g., days 3-4). 3, 4 The first report of the TNFα response in children with MODS found increased risks for nosocomial infection and death in subjects whose immunoparalysis persisted beyond day 3 of MODS, though very early samples were rare in that cohort. 2 Subsequent single-and multicenter studies have shown increased risks for prolonged organ dysfunction and death associated with severe suppression of the TNFα response and/or lymphocyte responsiveness as early as 1 to 2 days after sepsis onset. 8, 9 The significance of early versus late immunoparalysis as it relates to reversibility and outcomes remains unclear.
History of Immunomodulation in Sepsis
The 1980s and 1990s saw multiple phase II and III clinical trials of therapeutics designed to reduce the proinflammatory response to sepsis in adults. These included drugs to block or bind LPS, IL-1β, TNFα, and bradykinin as well as potent glucocorticoids, such as methylprednisolone or dexamethasone. [16] [17] [18] [19] [20] [21] [22] [23] These treatments consistently failed to improve outcomes and were occasionally associated with increased mortality. There were a few notable exceptions including the MONARCS trial in which a mortality benefit was seen in septic adults treated with anti-TNFα therapy but only if their initial plasma IL-6 levels were > 1,000 pg/mL. 24 Similarly, a secondary analysis of a large trial of IL-1 receptor antagonist suggested benefit in the subset of subjects who had hepatobiliary dysfunction and disseminated intravascular coagulation (chosen as a surrogate for macrophage activation syndrome [MAS]). 25 Lastly, anecdotal evidence has suggested improved outcomes from the use of anti-IL-6 antibodies in children with severe cytokine release syndrome following chimeric antigen receptor (CAR) T cell therapy. 26 Together, these data suggest that broad use of anti-inflammatory therapies likely has little place in acute sepsis management. Rather, there may be a role for the targeted use of selected anti-inflammatory drugs in septic patients with documented, severe hyperinflammation or in specific pathophysiologic states such as MAS.
Immunostimulatory Therapies in Sepsis
One possible reason for the failure of anti-inflammatory therapies in sepsis is that they may exacerbate or perpetuate sepsis-induced immune suppression. Immunoparalysis itself has become a target for immunomoduation in recent years, prompting a paradigm shift toward the use of immunostimulatory therapies in adults and children with severe immune suppression. The approaches were developed in response to the finding that immunoparalysis appears to be reversible. Fumeaux and Pugin were able to demonstrate restoration of HLA-DR expression in immunoparalyzed monocytes after ex vivo incubation with anti-IL-10 neutralizing antibodies. 27 Since then several approaches to immunostimlation in septic patients have been evaluated (►Table 2). 2, 6, [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] The use of recombinant IFNγ has been shown, in several small European case series, to be associated with improved mHLA-DR expression and TNFα response in septic adults with immunoparalysis. 28, 29 Interferon-γ is currently being evaluated for the reversal of immunoparalysis (mHLA-DR < 30%) in a multicenter, European randomized controlled trial (RCT) in septic adults (NCT03332225).
Granulocyte macrophage colony-stimulating factor (GM-CSF) is a cytokine that is made by T H 1 lymphocytes but is also available in recombinant form. GM-CSF was approved by the Food and Drug Administration (FDA) in 1991 for the restoration of bone marrow function following bone marrow transplantation and chemotherapy. In addition to its favorable side effect profile, GM-CSF represents an attractive candidate for the reversal of immunoparalysis in that it is capable of improving immune function in existing cells in addition to promoting the development of new cells of the monocyte and neutrophil lineages. Rosenbloom et al showed, in a small single-center RCT, that treatment with GM-CSF can result in improved mHLA-DR expression in septic adults, though enrollment was not limited to those with immunoparaly-sis. 34 Meisel et al subsequently showed, in a 38-subject RCT of septic adults with proven, severe reduction in mHLA-DR expression that GM-CSF treatment was associated with prompt recovery of mHLA-DR expression and TNFα response. 6 A similar single-center RCT was performed in septic children with MODS who demonstrated severe reduction in TNFα response (< 200 pg/mL). 2 In this study, 14 subjects were randomized to a week of GM-CSF or standard therapy. Those receiving GM-CSF showed recovery of the TNFα response to normal levels by the end of the week of treatment, while the standard therapy arm had a much more modest response (►Fig. 2). Interestingly, all of the subjects in the standard therapy arm developed a nosocomial infection while none were noted in the GM-CSF-treated group. The adaptive immune system may also represent a target for immunostimulation in septic patients with immunoparalysis. While lymphocyte-specific colony stimulating factors are not available, several other approaches have shown promise in preclinical models. IL-7 inhibits lymphocyte apoptosis and enhances lymphocyte responsiveness in vitro. In murine studies, administration of recombinant IL-7 was associated with improved lymphocyte function and survival in a two-hit model of peritonitis and candida pneumonia. 40 The programmed death (PD)-1 pathway represents another potential target for immunomodulatory therapy in sepsis. PD-1 is a coinhibitory molecule expressed by lymphocytes and binding by its ligands PD-L1 or PD-L2 on antigen presenting cells results in lymphocyte deactivation and/or apoptosis. Anti-PD-1 antibodies are FDA-approved as immunotherapy to promote lymphocyte responses against some forms of cancer. These have also been evaluated in murine models of sepsis, with improvements in innate and adaptive immune function and improved survival reported. 41, 42 At least one blocking antibody in the PD-1 family has been evaluated in human sepsis (NCT02576457) though results have not yet been reported. Interestingly, preclinical data suggest that combinatorial therapy with anti-PD-1 antibodies and recombinant IL-7 may more beneficial than either alone. 39 
Unintended Immunomodulation
While the prior section focused on intentional immunomodulation, it must be acknowledged that a great many therapies that are routinely employed in the care of children with sepsis have unintended immunologic effects, most of which are immunosuppressive. Red blood cell (RBC) transfusion, for example, may reduce leukocyte function as has been demonstrated in vitro and in septic children. 43, 44 The use of therapeutic hypothermia is known to reduce neutrophil function. 45 Many of the drugs in the ICU (intensive care unit) pharmacopeia are, in fact, immunomodulators (►Table 3). The clinical relevance of the individual and net effects of these therapies on immune function remains unknown and represents a crucial gap in our understanding of ICU pathophysiology. In addition to identifying treating patients with immunoparalysis, there is a great need for the development and testing of immunefriendly treatment regimens that may prevent the development of immunoparalysis in some cases.
Summary and Future Directions
The immune response to sepsis is highly dynamic and has both pro-and anti-inflammatory components. The presence of high levels of systemic inflammation, with accompanying symptoms of SIRS, doesnot rule out the presence of a compensatory anti-inflammatory response which may in itself be pathologic. Early attempts at immunomodulation in sepsis were likely flawed due to their singular focus on reduction of the proinflammatory response without measuring resultant effects on immune cell function. While some patients with severe inflammation may benefit from anti-inflammatory therapies, it is likely that these therapies should be carefully targeted, of short duration, and accompanied by immune function monitoring. Conversely, many patients with sepsis may benefit from immune stimulation to reverse immunoparalysis and restore the ability to clear infection, survey for and combat new infection, and remodel injured tissues. There are several therapies that show promise for the reversal of innate immune suppression in sepsis of which GM-CSF has the largest body of evidence to date. Strategies that target restoration of lymphocyte function in sepsis are under development as well. It is likely that a combinatorial approach, driven by prospective immune function testing of the innate and adaptive arms of the immune system, will be needed in some patients to achieve "IFN-γ production Abbreviations: ALI, acute lung injury; ARDS, acute respiratory distress syndrome; G-CSF, granulocyte colony stimulating factor; GM-CSF, granulocyte macrophage colony stimulating factor; ICU, intensive care unit; IFN-γ, interferon gamma; IL, interleukin; mHLA-DR, monocyte human leukocyte antigen-DR expression; MODS, multiple organ dysfunction syndrome; PD, programed death; RCT, randomized controlled trial; TNF, tumor necrosis factor. Note: Up arrows indicate increase, down arrows indicate decrease. though the largest body of data on the TNFα response in critical illness comes from the pediatric population, the vast majority of immunomodulation data can be found in the adult literature. The development of multicenter, prospective immune function monitoring, and modulation studies in septic children will be essential to safely bring these therapies into the pediatric ICU and improve outcomes in this vulnerable population. 
